Medicamen Lifesciences - Leading Pharmaceutical Innovation

About Medicamen Biotech Limited

Medicamen Biotech Limited ranks among the leading pharmaceutical companies with a focus on delivering affordable, high-quality medicines worldwide. Medicamen envisions its future as a global leader in this field. Medicamen operates WHO-GMP certified facilities in more than 35 countries, driving forward innovation and geographic expansion.

Established in December 1993, Medicamen has evolved into a fully integrated pharmaceutical company, with expertise in research, Active Pharmaceutical Ingredient (API) manufacturing and finished formulations. The Company's growth is supported by solid infrastructure and innovation-led systems focused on quality and affordability, enabling success in both regulated and semi-regulated markets.

Currently, the Company is developing general formulations intended for EU filings. Medicamen is also actively expanding its oncology portfolio in Europe, Latin America, Asia- Pacific and MENA through strategic partnerships, reinforcing its path to global leadership in oncology generics.

Our Journey

Year 1993-2000

1993 : Medicamen Biotech established
1995 : IPO issued-BSE listed
1996 : Operations started – Bhiwadi FDF Plant

Year 2001-2010

2001 : Global Accreditation NDA (Uganda), ANVISA (Brazil, FM HACA (Ethiopia- Received-Bhiwadi FDF Plant
2007 : Operations started-Haridwar Unit-I (FDF)

Year 2024...

2024 : Bhiwadi FDF Plant: Received approval of PIC/S & EU GMP – European
Haridwar Unit 2 Plant: Received accreditation of USFDA
Dahej API Plant: Received accreditation of USFDA

Year 2011-2020

2018 : New R&D center setup along with upgradation & Modernization of Bhiwadi FDF Plant
2016 : Shivalik Rasayan Ltd take controlling stake of Medicamen Biotech Ltd
2019 : Global Accreditation FABD (Philippines), CEOMED (Cuba)- Bhiwadi FDF Plant
2020 : Global API Facility started-Dahej API Plant

Year 2021-2023

2021 : Operations started : Haridwar formulation Unit – II (FDF) (oncology)
2021 : Filling API USDMFs & CEPs
2022 : Started new venture Medicamen Lifesciences
2023 : Filed its first Abbreviated New Drug Application (ANDA) for 'BORTEZOMIB injection 2mg' with (USFDA).

Global Presence

Where Markets Meet Momentum

Medicamen has established a global footprint covering over 35 countries. The Company has completed regulatory filings across Africa, along with submissions in Canada, Australia and Vietnam. With these regulatory efforts underway, the Company is moving forward with market entry strategies, partnerships and product rollouts worldwide.

100+ Pharmaceutical offerings distributed in 35+ countries worldwide